IP Library › Granted Patent US 12,318,356
Granted Patent B2
US 12,318,356 · App. 18/186,792 · Granted Jun 3, 2025

Use of cannabinoids in the treatment of epilepsy

Inventors: Geoffrey Guy (Cambridge, GB); Stephen Wright (Altrincham, GB); Orrin Devinsky (New York, NY)
Assignee: Jazz Pharmaceuticals Research UK Limited
A61K31/05A61K9/08A61K31/352A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,356
App. No.
18/186,792
Granted
Jun 3, 2025
Kind
B2
Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Claims (27)

1. A method of treating a typical absence seizure in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a cannabidiol (CBD) drug substance, wherein the CBD drug substance comprises at least 98% w/w CBD; and

wherein the dose of CBD administered to the patient ranges from about 5 mg/kg/day to about 25 mg/kg/day.

2. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD and not more than 0.15% w/w CBDA.

3. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD and not more than 1.0% w/w CBDV.

4. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD and not more than 0.15% w/w Δ9THC.

5. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD and not more than 0.5% w/w CBD-C4.

6. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD, not more than 1.0% w/w CBDV, and not more than 0.15% w/w Δ9THC.

7. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD, not more than 1.0% w/w CBDV, not more than 0.15% w/w Δ9THC, and not more than 0.5% w/w CBD-C4.

8. The method of claim 1 , wherein the CBD drug substance comprises at least 98% w/w CBD, not more than 0.15% w/w CBDA, not more than 1.0% w/w CBDV, not more than 0.15% w/w Δ9THC, and not more than 0.5% w/w CBD-C4.

9. The method of claim 1 , wherein the administering reduces the number of typical absence seizures compared to baseline.

10. The method of claim 1 , wherein the administering reduces typical absence seizure frequency compared to baseline.

11. The method of claim 1 , wherein the administering reduces typical absence seizure frequency by at least 50% compared to the typical absence seizure frequency experienced during a baseline period before CBD was administered.

12. The method of claim 8 , wherein the administering reduces the number of typical absence seizures compared to baseline.

13. The method of claim 8 , wherein the administering reduces typical absence seizure frequency compared to baseline.

14. The method of claim 8 , wherein the administering reduces typical absence seizure frequency by at least 50% compared to the typical absence seizure frequency experienced during a baseline period before CBD was administered.

15. The method of claim 1 , wherein the dose of CBD is 10 mg/kg/day.

16. The method of claim 1 , wherein the dose of CBD is 20 mg/kg/day.

17. The method of claim 15 , wherein the administering reduces the number of typical absence seizures compared to baseline.

18. The method of claim 15 , wherein the administering reduces typical absence seizure frequency compared to baseline.

19. The method of claim 15 , wherein the administering reduces typical absence seizure frequency by at least 50% compared to the typical absence seizure frequency experienced during a baseline period before CBD was administered.

20. The method of claim 16 , wherein the administering reduces typical absence seizures compared to baseline.

21. The method of claim 16 , wherein the administering reduces typical absence seizure frequency compared to baseline.

22. The method of claim 16 , wherein the administering reduces typical absence seizure frequency by at least 50% compared to the typical absence seizure frequency experienced during a baseline period before CBD was administered.

23. The method of claim 1 , wherein the dose of CBD administered to the patient ranges from about 10 mg/kg/day to about 20 mg/kg/day.

24. The method of claim 23 , wherein the administering reduces the number of typical absence seizures compared to baseline.

25. The method of claim 23 , wherein the administering reduces typical absence seizure frequency compared to baseline.

26. The method of claim 23 , wherein the administering reduces typical absence seizure frequency by at least 50% compared to the typical absence seizure frequency experienced during a baseline period before CBD was administered.

Assignments (4)
SECURITY AGREEMENT Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
CHANGE OF NAME Recorded May 16, 2024
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 067437/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2023
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 063459/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2023
From: GUY, GEOFFREY; WRIGHT, STEPHEN; DEVINSKY, ORRIN
To: GW PHARMA LIMITED
Reel/Frame 063262/0778 →
Continuity (9)
Continuation 17819046 · Aug 11, 2022
Continuation 17477172 · Sep 16, 2021
Continuation 17242075 · Apr 27, 2021
Continuation 17198965 · Mar 11, 2021
Continuation 16911914 · Jun 25, 2020
Continuation 16198141 · Nov 21, 2018
Continuation 15449535 · Mar 3, 2017
Continuation 14881969 · Oct 13, 2015
Related Publication 20230248664A1 · Aug 10, 2023
References Cited (400)
US 2304669A · Adams · 1942 [cited by applicant]
US 6383513B1 · Watts et al. · 2002 [cited by applicant]
US 6403126B1 · Webster · 2002 [cited by applicant]
US 6949582B1 · Wallace · 2005 [cited by applicant]
US 7025992B2 · Whittle et al. · 2006 [cited by applicant]
US 8222292B2 · Goskonda et al. · 2012 [cited by applicant]
US 8293786B2 · Stinchcomb · 2012 [cited by applicant]
US 8603515B2 · Whittle · 2013 [cited by applicant]
US 8632825B2 · Velasco Diez et al. · 2014 [cited by applicant]
US 8673368B2 · Guy et al. · 2014 [cited by applicant]
US 8790719B2 · Parolaro et al. · 2014 [cited by applicant]
US 9017737B2 · Kikuchi et al. · 2015 [cited by applicant]
US 9023322B2 · Van Damme et al. · 2015 [cited by applicant]
US 9066920B2 · Whalley et al. · 2015 [cited by applicant]
US 9095554B2 · Lewis et al. · 2015 [cited by applicant]
US 9095555B2 · Winnicki · 2015 [cited by applicant]
US 9125859B2 · Whalley et al. · 2015 [cited by applicant]
US 9168278B2 · Guy et al. · 2015 [cited by applicant]
US 9259449B2 · Raderman · 2016 [cited by applicant]
US 9474726B2 · Guy et al. · 2016 [cited by applicant]
US 9477019B2 · Li et al. · 2016 [cited by applicant]
US 9492438B2 · Pollard · 2016 [cited by applicant]
US 9522123B2 · Whalley et al. · 2016 [cited by applicant]
US 9630941B2 · Elsohly et al. · 2017 [cited by applicant]
US 9675654B2 · Parolaro et al. · 2017 [cited by applicant]
US 9680796B2 · Miller et al. · 2017 [cited by applicant]
US 9730911B2 · Verzura et al. · 2017 [cited by applicant]
US 9949936B2 · Guy et al. · 2018 [cited by applicant]
US 9949937B2 · Guy et al. · 2018 [cited by applicant]
US 9956183B2 · Guy et al. · 2018 [cited by applicant]
US 9956184B2 · Guy et al. · 2018 [cited by applicant]
US 9956185B2 · Guy et al. · 2018 [cited by applicant]
US 9956186B2 · Guy et al. · 2018 [cited by applicant]
US 9962341B2 · Stott et al. · 2018 [cited by applicant]
US 10039724B2 · Stott et al. · 2018 [cited by applicant]
US 10092525B2 · Guy et al. · 2018 [cited by applicant]
US 10098867B2 · Javid et al. · 2018 [cited by applicant]
US 10111840B2 · Guy et al. · 2018 [cited by applicant]
US 10137095B2 · Guy et al. · 2018 [cited by applicant]
US 10220005B2 · Martinez-Orgado · 2019 [cited by applicant]
US 10226433B2 · DiMarzo et al. · 2019 [cited by applicant]
US 10583096B2 · Guy et al. · 2020 [cited by applicant]
US 10603288B2 · Guy et al. · 2020 [cited by applicant]
US 10653641B2 · Robson et al. · 2020 [cited by applicant]
US 10709671B2 · Guy et al. · 2020 [cited by applicant]
US 10709673B2 · Guy et al. · 2020 [cited by applicant]
US 10709674B2 · Guy et al. · 2020 [cited by applicant]
US 10729665B2 · Whalley et al. · 2020 [cited by applicant]
US 10758514B2 · Liu et al. · 2020 [cited by applicant]
US 10765643B2 · Guy et al. · 2020 [cited by applicant]
US 10799467B2 · Whalley et al. · 2020 [cited by applicant]
US 10807777B2 · Whittle · 2020 [cited by applicant]
US 10849860B2 · Guy et al. · 2020 [cited by applicant]
US 10918608B2 · Guy et al. · 2021 [cited by applicant]
US 10925525B2 · Nakaji · 2021 [cited by applicant]
US 10966939B2 · Guy et al. · 2021 [cited by applicant]
US 11000486B2 · Liu et al. · 2021 [cited by applicant]
US 11065209B2 · Guy et al. · 2021 [cited by applicant]
US 11065227B2 · Stott et al. · 2021 [cited by applicant]
US 11096905B2 · Guy et al. · 2021 [cited by applicant]
US 11147776B2 · Stott et al. · 2021 [cited by applicant]
US 11147783B2 · Stott et al. · 2021 [cited by applicant]
US 11154516B2 · Guy et al. · 2021 [cited by applicant]
US 11154517B2 · Guy et al. · 2021 [cited by applicant]
US 11160757B1 · Wilkhu et al. · 2021 [cited by applicant]
US 11160795B2 · Guy et al. · 2021 [cited by applicant]
US 11207292B2 · Guy et al. · 2021 [cited by applicant]
US 11224600B2 · Vangara et al. · 2022 [cited by applicant]
US 11229612B2 · Wright et al. · 2022 [cited by applicant]
US 11291631B2 · Shah · 2022 [cited by applicant]
US 11311498B2 · Guy et al. · 2022 [cited by applicant]
US 11318109B2 · Whalley et al. · 2022 [cited by applicant]
US 11331279B2 · Vangara et al. · 2022 [cited by applicant]
US 11357741B2 · Guy et al. · 2022 [cited by applicant]
US 11400055B2 · Guy et al. · 2022 [cited by applicant]
US 11406623B2 · Guy et al. · 2022 [cited by applicant]
US 11413266B2 · Biro et al. · 2022 [cited by applicant]
US 11419829B2 · Whalley et al. · 2022 [cited by applicant]
US 11426362B2 · Wright et al. · 2022 [cited by applicant]
US 11446258B2 · Guy et al. · 2022 [cited by applicant]
US 11590087B2 · Guy et al. · 2023 [cited by applicant]
US 11633369B2 · Guy et al. · 2023 [cited by applicant]
US 11679087B2 · Guy et al. · 2023 [cited by applicant]
US 11684598B2 · Stott et al. · 2023 [cited by applicant]
US 11701330B2 · Guy et al. · 2023 [cited by applicant]
US 11709671B2 · Joubert et al. · 2023 [cited by applicant]
US 11766411B2 · Guy et al. · 2023 [cited by applicant]
US 11793770B2 · Stott et al. · 2023 [cited by applicant]
US 11806319B2 · Wilkhu et al. · 2023 [cited by applicant]
US 11865102B2 · Guy et al. · 2024 [cited by applicant]
US 11963937B2 · Guy et al. · 2024 [cited by applicant]
US 12023305B2 · Whalley et al. · 2024 [cited by applicant]
US 12064399B2 · Guy et al. · 2024 [cited by applicant]
US 20040034108A1 · Whittle · 2004 [cited by applicant]
US 20040049059A1 · Mueller · 2004 [cited by applicant]
US 20040110828A1 · Chowdhury et al. · 2004 [cited by applicant]
US 20040147767A1 · Whittle et al. · 2004 [cited by applicant]
US 20050042172A1 · Whittle · 2005 [cited by applicant]
US 20050266108A1 · Flockhart et al. · 2005 [cited by applicant]
US 20060039959A1 · Wessling · 2006 [cited by applicant]
US 20060167283A1 · Flockhart et al. · 2006 [cited by applicant]
US 20070060638A1 · Olmstead · 2007 [cited by applicant]
US 20070099987A1 · Weiss et al. · 2007 [cited by applicant]
US 20070238786A1 · Hobden et al. · 2007 [cited by applicant]
US 20080112895A1 · Kottayil et al. · 2008 [cited by applicant]
US 20080119544A1 · Guy et al. · 2008 [cited by applicant]
US 20080188461A1 · Guan · 2008 [cited by applicant]
US 20090036523A1 · Stinchcomb et al. · 2009 [cited by applicant]
US 20090264063A1 · Tinsley et al. · 2009 [cited by applicant]
US 20090306221A1 · Guy et al. · 2009 [cited by applicant]
US 20100239693A1 · Guy et al. · 2010 [cited by applicant]
US 20100273895A1 · Stinchcomb et al. · 2010 [cited by applicant]
US 20100317729A1 · Guy et al. · 2010 [cited by applicant]
US 20110028431A1 · Zerbe et al. · 2011 [cited by applicant]
US 20110033529A1 · Samantaray et al. · 2011 [cited by applicant]
US 20110038958A1 · Kikuchi et al. · 2011 [cited by applicant]
US 20110082195A1 · Guy et al. · 2011 [cited by applicant]
US 20110150825A1 · Buggy et al. · 2011 [cited by applicant]
US 20120004251A1 · Whalley et al. · 2012 [cited by applicant]
US 20120165402A1 · Whalley et al. · 2012 [cited by applicant]
US 20120183606A1 · Bender et al. · 2012 [cited by applicant]
US 20120202891A1 · Stinchcomb et al. · 2012 [cited by applicant]
US 20120270845A1 · Bannister · 2012 [cited by applicant]
US 20130143894A1 · Bergstrom et al. · 2013 [cited by applicant]
US 20130209483A1 · McAllister · 2013 [cited by applicant]
US 20130245110A1 · Guy et al. · 2013 [cited by applicant]
US 20130296398A1 · Whalley et al. · 2013 [cited by applicant]
US 20140100269A1 · Goskonda et al. · 2014 [cited by applicant]
US 20140155456A9 · Whalley et al. · 2014 [cited by applicant]
US 20140243405A1 · Whalley et al. · 2014 [cited by applicant]
US 20140335208A1 · Cawthorne et al. · 2014 [cited by applicant]
US 20140343044A1 · Ceulemens · 2014 [cited by applicant]
US 20150111939A1 · Gruening et al. · 2015 [cited by applicant]
US 20150181924A1 · Llamas · 2015 [cited by applicant]
US 20150320698A1 · Whalley et al. · 2015 [cited by applicant]
US 20150335590A1 · Whalley et al. · 2015 [cited by applicant]
US 20150342902A1 · Vangara et al. · 2015 [cited by applicant]
US 20150343071A1 · Vangara et al. · 2015 [cited by applicant]
US 20150359755A1 · Guy et al. · 2015 [cited by applicant]
US 20150359756A1 · Guy et al. · 2015 [cited by applicant]
US 20160010126A1 · Poulos et al. · 2016 [cited by applicant]
US 20160166498A1 · Anastassov · 2016 [cited by applicant]
US 20160166514A1 · Guy et al. · 2016 [cited by applicant]
US 20160166515A1 · Guy et al. · 2016 [cited by applicant]
US 20160220529A1 · Guy et al. · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160317468A1 · Sankar et al. · 2016 [cited by applicant]
US 20160338974A1 · Aung-Din · 2016 [cited by applicant]
US 20170007551A1 · Guy et al. · 2017 [cited by applicant]
US 20170008868A1 · Dialer et al. · 2017 [cited by applicant]
US 20170172939A1 · Guy et al. · 2017 [cited by applicant]
US 20170172940A1 · Guy et al. · 2017 [cited by applicant]
US 20170172941A1 · Guy et al. · 2017 [cited by applicant]
US 20170173043A1 · Guy et al. · 2017 [cited by applicant]
US 20170173044A1 · Guy et al. · 2017 [cited by applicant]
US 20170181982A1 · Guy et al. · 2017 [cited by applicant]
US 20170224634A1 · Vangara et al. · 2017 [cited by applicant]
US 20170231923A1 · Guy et al. · 2017 [cited by applicant]
US 20170239193A1 · Guy et al. · 2017 [cited by applicant]
US 20170246121A1 · Guy et al. · 2017 [cited by applicant]
US 20170266126A1 · Guy et al. · 2017 [cited by applicant]
US 20170273913A1 · Wilkhu et al. · 2017 [cited by applicant]
US 20180028489A1 · Vangara et al. · 2018 [cited by applicant]
US 20180071210A1 · Wilkhu et al. · 2018 [cited by applicant]
US 20180228751A1 · Stott et al. · 2018 [cited by applicant]
US 20180338931A1 · Guy et al. · 2018 [cited by applicant]
US 20190031601A1 · Elsohly et al. · 2019 [cited by applicant]
US 20190083418A1 · Guy et al. · 2019 [cited by applicant]
US 20190091171A1 · Guy et al. · 2019 [cited by applicant]
US 20190160393A1 · Marshall et al. · 2019 [cited by applicant]
US 20190167583A1 · Shah · 2019 [cited by applicant]
US 20190175547A1 · Stott et al. · 2019 [cited by applicant]
US 20190247324A1 · Whalley et al. · 2019 [cited by applicant]
US 20190314296A1 · Wright et al. · 2019 [cited by applicant]
US 20190321307A1 · Guy et al. · 2019 [cited by applicant]
US 20190365667A1 · Wright et al. · 2019 [cited by applicant]
US 20200000741A1 · Guy et al. · 2020 [cited by applicant]
US 20200069608A1 · Guy et al. · 2020 [cited by applicant]
US 20200138738A1 · Guy et al. · 2020 [cited by applicant]
US 20200179303A1 · Guy et al. · 2020 [cited by applicant]
US 20200206152A1 · Stott et al. · 2020 [cited by applicant]
US 20200206153A1 · Whalley et al. · 2020 [cited by applicant]
US 20200237683A1 · Whalley et al. · 2020 [cited by applicant]
US 20200297656A1 · Guy et al. · 2020 [cited by applicant]
US 20200323792A1 · Guy et al. · 2020 [cited by applicant]
US 20200352878A1 · Guy et al. · 2020 [cited by applicant]
US 20200368179A1 · Guy et al. · 2020 [cited by applicant]
US 20210015789A1 · Guy et al. · 2021 [cited by applicant]
US 20210052512A1 · Guy et al. · 2021 [cited by applicant]
US 20210059949A1 · Wilkhu et al. · 2021 [cited by applicant]
US 20210059960A1 · Wilkhu et al. · 2021 [cited by applicant]
US 20210059976A1 · Wilkhu et al. · 2021 [cited by applicant]
US 20210069333A1 · Velasco Diez et al. · 2021 [cited by applicant]
US 20210093581A1 · Guy et al. · 2021 [cited by applicant]
US 20210100755A1 · Whalley et al. · 2021 [cited by applicant]
US 20210145765A1 · Guy et al. · 2021 [cited by applicant]
US 20210169824A1 · Guy et al. · 2021 [cited by applicant]
US 20210177773A1 · Guy et al. · 2021 [cited by applicant]
US 20210196651A1 · Guy et al. · 2021 [cited by applicant]
US 20210230145A1 · Blankman et al. · 2021 [cited by applicant]
US 20210244685A1 · Guy et al. · 2021 [cited by applicant]
US 20210167950A1 · Guy et al. · 2021 [cited by applicant]
US 20210290565A1 · Guy et al. · 2021 [cited by applicant]
US 20210308072A1 · Wright et al. · 2021 [cited by applicant]
US 20210330636A1 · Guy et al. · 2021 [cited by applicant]
US 20210401771A1 · Guy et al. · 2021 [cited by applicant]
US 20220000800A1 · Guy et al. · 2022 [cited by applicant]
US 20220008355A1 · Guy et al. · 2022 [cited by applicant]
US 20220016048A1 · Guy et al. · 2022 [cited by applicant]
US 20220023232A1 · Guy et al. · 2022 [cited by applicant]
US 20220040155A1 · Guy et al. · 2022 [cited by applicant]
US 20220062197A1 · Stott et al. · 2022 [cited by applicant]
US 20220062211A1 · Stott et al. · 2022 [cited by applicant]
US 20220087951A1 · Guy et al. · 2022 [cited by applicant]
US 20220096397A1 · Wright et al. · 2022 [cited by applicant]
US 20220168266A1 · Guy et al. · 2022 [cited by applicant]
US 20220183997A1 · Guy et al. · 2022 [cited by applicant]
US 20220184000A1 · Guy et al. · 2022 [cited by applicant]
US 20220202738A1 · Guy et al. · 2022 [cited by applicant]
US 20220211629A1 · Wilkhu et al. · 2022 [cited by applicant]
US 20220226257A1 · Guy et al. · 2022 [cited by applicant]
US 20220233495A1 · Silcock et al. · 2022 [cited by applicant]
US 20220249396A1 · Guy et al. · 2022 [cited by applicant]
US 20220257529A1 · Guy et al. · 2022 [cited by applicant]
US 20220265573A1 · Guy et al. · 2022 [cited by applicant]
US 20220288055A1 · Silcock et al. · 2022 [cited by applicant]
US 20220323375A1 · Guy et al. · 2022 [cited by applicant]
US 20220362149A1 · Shah · 2022 [cited by applicant]
US 20220378714A1 · Guy et al. · 2022 [cited by applicant]
US 20220378715A1 · Guy et al. · 2022 [cited by applicant]
US 20220378717A1 · Guy et al. · 2022 [cited by applicant]
US 20220378738A1 · Guy et al. · 2022 [cited by applicant]
US 20220387347A1 · Whalley et al. · 2022 [cited by applicant]
US 20220395470A1 · Whalley et al. · 2022 [cited by applicant]
US 20220395471A1 · Guy et al. · 2022 [cited by applicant]
US 20230000789A1 · Guy et al. · 2023 [cited by applicant]
US 20230022487A1 · Guy et al. · 2023 [cited by applicant]
US 20230024312A1 · Whalley et al. · 2023 [cited by applicant]
US 20230026079A1 · Guy et al. · 2023 [cited by applicant]
US 20230032502A1 · Guy et al. · 2023 [cited by applicant]
US 20230038423A1 · Silcock et al. · 2023 [cited by applicant]
US 20230068885A1 · Guy et al. · 2023 [cited by applicant]
US 20230143812A1 · Knappertz et al. · 2023 [cited by applicant]
US 20230235825A1 · Thompson et al. · 2023 [cited by applicant]
US 20230263744A1 · Guy et al. · 2023 [cited by applicant]
US 20230277560A1 · Checketts et al. · 2023 [cited by applicant]
US 20230277561A1 · Checketts et al. · 2023 [cited by applicant]
US 20230277562A1 · Checketts et al. · 2023 [cited by applicant]
US 20230277563A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285419A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285420A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285421A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285422A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285423A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285424A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285425A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285426A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285427A1 · Checketts et al. · 2023 [cited by applicant]
US 20230285428A1 · Checketts et al. · 2023 [cited by applicant]
US 20230301934A1 · Whalley et al. · 2023 [cited by applicant]
US 20230301936A1 · Guy et al. · 2023 [cited by applicant]
US 20230310464A1 · Checketts et al. · 2023 [cited by applicant]
US 20230346809A1 · Craig et al. · 2023 [cited by applicant]
US 20230372367A1 · Checketts et al. · 2023 [cited by applicant]
US 20230372368A1 · Checketts et al. · 2023 [cited by applicant]
US 20240016819A1 · Craig et al. · 2024 [cited by applicant]
US 20240025858A1 · Silcock et al. · 2024 [cited by applicant]
US 20240033229A1 · Guy et al. · 2024 [cited by applicant]
US 20240043388A1 · Silcock et al. · 2024 [cited by applicant]
US 20240050452A1 · Craig et al. · 2024 [cited by applicant]
US 20240091241A1 · Guy et al. · 2024 [cited by applicant]
US 20240130981A1 · Wilkhu et al. · 2024 [cited by applicant]
US 20240131041A1 · Tse et al. · 2024 [cited by applicant]
US 20240165048A1 · Guy et al. · 2024 [cited by applicant]
US 20240207220A1 · Guy et al. · 2024 [cited by applicant]
US 20240215910A1 · Tse et al. · 2024 [cited by applicant]
US 20240226032A9 · Wilkhu et al. · 2024 [cited by applicant]
US 20240226123A9 · Tse et al. · 2024 [cited by applicant]
US 20240238218A1 · Silcock et al. · 2024 [cited by applicant]
US 20240254066A1 · Silcock et al. · 2024 [cited by applicant]
US 20240254072A1 · Silcock et al. · 2024 [cited by applicant]
US 20240261234A1 · Guy et al. · 2024 [cited by applicant]
US 20240293762A1 · Loft et al. · 2024 [cited by applicant]
CA 2737447A1 · 2012 [cited by applicant]
CA 2859934A1 · 2016 [cited by applicant]
CN 101040855A · 2007 [cited by applicant]
CN 103110582A · 2013 [cited by applicant]
CN 104490873A · 2015 [cited by applicant]
CN 108236608A · 2018 [cited by applicant]
CN 110215443A · 2019 [cited by applicant]
CN 110279617A · 2019 [cited by applicant]
DE 102012105063A1 · 2013 [cited by applicant]
EP 1542657A1 · 2005 [cited by applicant]
EP 2311475A2 · 2011 [cited by applicant]
EP 2448637B1 · 2012 [cited by applicant]
EP 2578561A1 · 2013 [cited by applicant]
EP 3157512B1 · 2018 [cited by applicant]
GB 2002754A · 1979 [cited by applicant]
GB 2377633A · 2003 [cited by applicant]
GB 2380129A · 2003 [cited by applicant]
GB 2381194A · 2003 [cited by applicant]
GB 2384707A · 2003 [cited by applicant]
GB 2434097A · 2007 [cited by applicant]
GB 2434312A · 2007 [cited by applicant]
GB 2450753A · 2009 [cited by applicant]
GB 2456183A · 2009 [cited by applicant]
GB 2471523A · 2011 [cited by applicant]
GB 2478595A · 2011 [cited by applicant]
GB 2479153A · 2011 [cited by applicant]
GB 2485291A · 2012 [cited by applicant]
GB 2487183A · 2012 [cited by applicant]
GB 2471565B · 2012 [cited by applicant]
GB 2478072B · 2012 [cited by applicant]
GB 2478074B · 2012 [cited by applicant]
GB 2492487A · 2013 [cited by applicant]
GB 2487712A · 2015 [cited by applicant]
GB 2530001A · 2016 [cited by applicant]
GB 2531093A · 2016 [cited by applicant]
GB 2531278A · 2016 [cited by applicant]
GB 2531281A · 2016 [cited by applicant]
GB 2531282A · 2016 [cited by applicant]
GB 2539472A · 2016 [cited by applicant]
GB 2542155A · 2017 [cited by applicant]
GB 2551987A · 2018 [cited by applicant]
GB 2584140A · 2020 [cited by applicant]
WO WO0195899A2 · 2001 [cited by applicant]
WO WO2002064109A2 · 2002 [cited by applicant]
WO WO02089945A2 · 2002 [cited by applicant]
WO WO2003099302A1 · 2003 [cited by applicant]
WO WO2004016246A1 · 2004 [cited by applicant]
WO WO2004016277A2 · 2004 [cited by applicant]
WO WO2004026802A1 · 2004 [cited by applicant]
WO WO2005120478A1 · 2005 [cited by applicant]
WO WO2006054057A2 · 2006 [cited by applicant]
WO WO2006133941A2 · 2006 [cited by applicant]
WO WO2007032962A2 · 2007 [cited by applicant]
WO WO2007052013A1 · 2007 [cited by applicant]
WO WO2007083098A1 · 2007 [cited by applicant]
WO WO2007138322A1 · 2007 [cited by applicant]
WO WO2008094181A3 · 2008 [cited by applicant]
WO WO2008129258A1 · 2008 [cited by applicant]
WO WO2008021394A2 · 2008 [cited by applicant]
WO WO2008146006A1 · 2008 [cited by applicant]
WO WO2009007697A1 · 2009 [cited by applicant]
WO WO2009093018A1 · 2009 [cited by applicant]
WO WO2011001169A1 · 2011 [cited by applicant]
WO WO2011121351A1 · 2011 [cited by applicant]
WO WO2012093255A1 · 2012 [cited by applicant]
WO WO2012160358A1 · 2012 [cited by applicant]
WO WO2013032351A1 · 2013 [cited by applicant]
WO WO2013045891A1 · 2013 [cited by applicant]
WO WO2014168131A1 · 2013 [cited by applicant]
WO WO2014108899A1 · 2014 [cited by applicant]
WO WO2015142501A1 · 2015 [cited by applicant]
WO WO2015184127A2 · 2015 [cited by applicant]
WO WO2015193667A1 · 2015 [cited by applicant]
WO WO2015193668A1 · 2015 [cited by applicant]
WO WO2016059399A1 · 2016 [cited by applicant]
WO WO2016059403A1 · 2016 [cited by applicant]
WO WO2016059405A1 · 2016 [cited by applicant]
WO WO2015187988A1 · 2016 [cited by applicant]
WO WO2016118391A1 · 2016 [cited by applicant]
WO WO2016022936A1 · 2016 [cited by applicant]
WO WO2016176279A1 · 2016 [cited by applicant]
WO WO2016191651A1 · 2016 [cited by applicant]
WO WO2016203239A1 · 2016 [cited by applicant]
WO WO2017042567A1 · 2017 [cited by applicant]
WO WO2017139496A1 · 2017 [cited by applicant]
WO WO2017168138A1 · 2017 [cited by applicant]
WO WO2017203529A1 · 2017 [cited by applicant]
WO WO2017204986A1 · 2017 [cited by applicant]
WO WO2018002665A1 · 2018 [cited by applicant]
WO WO2018011808A1 · 2018 [cited by applicant]
WO WO2018115962A1 · 2018 [cited by applicant]
WO WO2018200024A1 · 2018 [cited by applicant]
WO WO2018234811A1 · 2018 [cited by applicant]
WO WO2019020738A1 · 2019 [cited by applicant]
WO WO2019097238A1 · 2019 [cited by applicant]
WO WO2019145700A1 · 2019 [cited by applicant]
WO WO2019207319A1 · 2019 [cited by applicant]
WO WO2019210210A1 · 2019 [cited by applicant]
WO WO2019211795A1 · 2019 [cited by applicant]
WO WO2020225540A1 · 2020 [cited by applicant]
WO WO2020234569A1 · 2020 [cited by applicant]
WO WO2021019231A1 · 2021 [cited by applicant]
U.S. Appl. No. 61/969,070, filed Mar. 21, 2014, Kane et al. [cited by applicant]
U.S. Appl. No. 62/004,495, filed May 29, 2014, Vangara et al. [cited by applicant]
U.S. Appl. No. 62/154,660, filed Apr. 29, 2015, Vangara et al. [cited by applicant]
U.S. Appl. No. 14/724,351, filed May 28, 2015, Vangara et al. [cited by applicant]
Notice of Opposition to European Patent Application No. EP15784111.5, Patent No. EP3206716, dated May 10, 2021, 25 pages. [cited by applicant]
Abati, E. et al., “Cannabidiol treatment of refractory epileptic spasms: an open label study,” American Epilepsy Society, Annual Meeting, Abstract 3.404, 2015, 2 pages; https://aesnet.org/abstractslisting/cannabidiol-tr… [cited by applicant]
Adams, R. et al., “Isolation of Cannabinol, Cannabidiol and Quebrachitol from Red Oil of Minnesota Wild Hemp,” J. Am. Chem. Soc. 1940, 62, 8, 2194-2196. [cited by applicant]
AFINITOR® (everolimus) tablets, for oral use, and AFINITOR DISPERZ® (everolimus tablets for oral suspension) Prescribing Information, 2009, 49 pages. [cited by applicant]
Aker, R. G. et al., “Chemically Induced Experimental Models of Absence Epilepsy,” Chemical-Induced Seizures: Mechanisms, Consequences and Treatment, Chapter 6, 2011, pp. 67-79. [cited by applicant]
Akiyama, M. et al., “Dravet Syndrome:A Genetic Epileptic Disorder,” Acta. Med. Okayama, 66(5):369-376 (2012). [cited by applicant]
Allen, J. W., “Clobazam as an adjunctive treatment in refractory epilepsy,” British Medical Journal, 286:1246-1247 (1983). [cited by applicant]
Arik, A. E. et al., “Effect of levetiracetam on penicillin induced epileptic activity in rats,” Acta Neurobiol Exp, 74:266-275 (2014). [cited by applicant]
Allen G., “Florida Bill Would Allow Medical Marijuana For Child Seizures,” Jan. 16, 2014, retrieved from https://www.npr.org/sections/health-shots/2014/01/16/262481852/florida-bill-would-allow-marijuana-extract-for-chil… [cited by applicant]
[Anonymous], “GW Pharma—GW Pharmaceuticals Announces New Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy,” Oct. 14, 2014; https://ir.gwpharm.com/news-relea… [cited by applicant]
[Anonymous], “GW Pharmaceuticals Announces Epidiolex Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome,” GW Pharmaceuticals Press Release dated Jun. 6, 2014; http://www.gwpharm.com/GW%20Pharm… [cited by applicant]
Cited By (3)
US 12,427,160 US 12,569,505 US 12,661,365